Comparative Effectiveness of SGLT2 Inhibitor and GLP-1 Receptor Agonist on Kidney and Cardiovascular Outcomes by Kidney Failure Risk
Journal of the American Society of Nephrology · 2026-08 · 37 (8) · 1733-1747
DOI: 10.1681/asn.0000001016 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Journal of the American Society of Nephrology, online erschienen am 13.01.2026. Verfasst von Sydney E Hartsell und 12 weiteren Autor:innen. Beteiligte Einrichtung: Cardiovascular, Renal and Metabolism Center, Spencer Fox Eccles School of Medicine, Salt Lake City, Utah. Hauptthemen laut MEDLINE: Glucagon-Like Peptide-1 Receptor Agonists, Diabetes Mellitus, Type 2, Sodium-Glucose Transporter 2 Inhibitors, Cardiovascular Diseases. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Kidney Foundation, NCATS NIH HHS, NIDDK NIH HHS.
Abstract (Originalsprache)
Key Points In veterans with type 2 diabetes and low kidney failure risk, sodium-glucose cotransporter 2 inhibitors (SGLT2is) were more kidney protective while glucagon-like peptide-1 receptor agonists (GLP-1 RAs) were more cardioprotective. For cardiovascular-kidney-metabolic outcomes, GLP-1 RAs were more protective at moderate kidney failure risk and SGLT2is were more protective at high kidney failure risk. The kidney failure risk equation might be a clinically useful tool to guide therapy in type 2 diabetes.
Background
Head-to-head comparisons of non-exendin glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium-glucose cotransporter 2 inhibitors (SGLT2is) on kidney failure or cardiovascular-kidney-metabolic (CKM) composite end points are lacking. Whether kidney failure risk modifies the comparative effectiveness of GLP-1 RA versus SGLT2i is clinically relevant.
Methods
We defined a national veterans cohort with type 2 diabetes who initiated an SGLT2i, non-exendin GLP-1 RA, or insulin glargine between January 1, 2018, and December 31, 2021. After applying inverse probability of treatment weighting to balance baseline characteristics, outcomes were compared across new-user groups through March 31, 2023. Outcomes included kidney failure (stage 5 CKD or long-term KRT), major adverse cardiovascular events (MACEs: heart failure, myocardial infarction, or stroke), CKM composite (kidney failure or MACE), all-cause death, and composites of outcomes with death. We tested for effect modification by the kidney failure risk equation (KFRE) score on comparative pairwise drug effectiveness.
Results
Out of 160,428 veterans, 53%, 14%, and 34% were new users of SGLT2i, GLP-1 RA, and insulin glargine, respectively. Relative to GLP-1 RA new-users, SGLT2i new-users had similar mortality risk, a trend toward lower kidney failure risk (hazard ratio [HR], 0.89; 95% confidence interval [CI], 0.74 to 1.06), but higher risk of MACE (HR, 1.14; 95% CI, 1.09 to 1.20) and CKM composite (HR, 1.13; 95% CI, 1.08 to 1.19). The effect of SGLT2i versus GLP-1 RA differed significantly between moderate-risk (2%–6%) and high-risk (≥6%) KFRE subgroups for all outcomes except all-cause death. In those with moderate-risk KFRE, GLP-1 RA seemed more protective for kidney failure, MACE, and CKM composite, while SGLT2i appeared more protective in those with high-risk KFRE.
Conclusions
Compared with GLP-1 RA, SGLT2i had comparable risks of mortality, perhaps a lower risk of kidney failure, but modestly higher risk of cardiovascular events in the entire cohort. However, GLP-1 RA were more beneficial in those with moderate kidney failure risk and SGLT2i more beneficial in those with high kidney failure risk. Podcast This article contains a podcast at https://dts.podtrac.com/redirect.mp3//www.asn-online.org/media/podcast/JASN/2026_07_29_KTS_July2026.mp3
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cardiovascular, Renal and Metabolism Center, Spencer Fox Eccles School of Medicine, Salt Lake City, Utah.
- Division of Nephrology and Hypertension, Department of Internal Medicine, Spencer Fox Eccles School of Medicine, Salt Lake City, Utah.
- George E. Whalen Department of Veterans Affairs Medical Center, Salt Lake City, Utah.
- Nora Eccles Harrison Cardiovascular Research and Training Institute, Spencer Fox Eccles School of Medicine, Salt Lake City, Utah.
- Division of Biostatistics, Department of Population Health Sciences, Spencer Fox Eccles School of Medicine, Salt Lake City, Utah.
- Informatics Decision Enhancement and Surveillance (IDEAS) Center, Veterans Affairs Salt Lake City Health Care System, Salt Lake City, Utah.
ORCID-Profile: Sydney E Hartsell, Guo Wei, Ravinder Singh, Michael Throolin, Catherine G Derington, Christa Curtis, Jincheng Shen, Tom Greene
Förderung
- National Kidney Foundation
- NCATS NIH HHS
- NIDDK NIH HHS
- Bayer
- NIA NIH HHS
- NHLBI NIH HHS
- National Heart, Lung, and Blood Institute
- National Institute of Diabetes and Digestive and Kidney Diseases
Zitieren
APA
Hartsell, S. E., Wei, G., Singh, R., Throolin, M., Nevers, M. R., Sarwal, A., Derington, C. G., Curtis, C., Boucher, R. E., Shen, J., Drakos, S., Greene, T., & Beddhu, S. (2026). Comparative Effectiveness of SGLT2 Inhibitor and GLP-1 Receptor Agonist on Kidney and Cardiovascular Outcomes by Kidney Failure Risk. Journal of the American Society of Nephrology, 37(8), 1733-1747. https://doi.org/10.1681/asn.0000001016
Vancouver
Hartsell SE, Wei G, Singh R, Throolin M, Nevers MR, Sarwal A, et al. Comparative Effectiveness of SGLT2 Inhibitor and GLP-1 Receptor Agonist on Kidney and Cardiovascular Outcomes by Kidney Failure Risk. Journal of the American Society of Nephrology. 2026;37(8):1733-1747. doi:10.1681/asn.0000001016
BibTeX
@article{Hartsell2026,
author = {Hartsell, Sydney E and Wei, Guo and Singh, Ravinder and Throolin, Michael and Nevers, McKenna R and Sarwal, Amara and Derington, Catherine G and Curtis, Christa and Boucher, Robert E and Shen, Jincheng and Drakos, Stavros and Greene, Tom and Beddhu, Srinivasan},
title = {Comparative Effectiveness of SGLT2 Inhibitor and GLP-1 Receptor Agonist on Kidney and Cardiovascular Outcomes by Kidney Failure Risk},
journal = {Journal of the American Society of Nephrology},
year = {2026},
volume = {37},
number = {8},
pages = {1733--1747},
doi = {10.1681/asn.0000001016}
}
EUVIMED